Search Results - "Boddy, A V"

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours by Plummer, R, Wilson, R H, Calvert, H, Boddy, A V, Griffin, M, Sludden, J, Tilby, M J, Eatock, M, Pearson, D G, Ottley, C J, Matsumura, Y, Kataoka, K, Nishiya, T

“…Background: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower…”
Get full text

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide by Bray, J, Sludden, J, Griffin, M J, Cole, M, Verrill, M, Jamieson, D, Boddy, A V

“…Background: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and…”
Get full text

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules by Murray, J, Thomas, H, Berry, P, Kyle, S, Patterson, M, Jones, C, Los, G, Hostomsky, Z, Plummer, E R, Boddy, A V, Curtin, N J

“…Background: Poly(ADP-ribose) polymerase-1 (PARP) inhibitors (PARPi) exploit tumour-specific defects in homologous recombination DNA repair and continuous…”
Get full text

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer by Pridgeon, S W, Heer, R, Taylor, G A, Newell, D R, O'Toole, K, Robinson, M, Xu, Y-Z, Karran, P, Boddy, A V

“…Background: Thiothymidine (S 4 TdR) can be incorporated into DNA and sensitise cells to DNA damage and cell death following exposure to UVA light. Studies were…”
Get full text

Estimation of glomerular filtration rate in cancer patients by WRIGHT, J. G, BODDY, A. V, HIGHLEY, M, FENWICK, J, MCGILL, A, CALVERT, A. H

“…The frequent need to obtain an estimate of renal function in cancer patients, not least for targeting carboplatin dose, has led to a number of approaches to…”
Get full text

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699 by Daniel, R A, Rozanska, A L, Mulligan, E A, Drew, Y, Thomas, H D, Castelbuono, D J, Hostomsky, Z, Plummer, E R, Tweddle, D A, Boddy, A V, Clifford, S C, Curtin, N J

“…Background: Temozolomide shows activity against medulloblastoma, the most common malignant paediatric brain tumour. Poly(ADP-ribose) polymerase (PARP)…”
Get full text

Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP‐glucuronosyltransferases by Illingworth, NA, Boddy, AV, Daly, AK, Veal, GJ

“…BACKGROUND AND PURPOSE Fenretinide (4‐HPR) is a retinoic acid analogue, currently used in clinical trials in oncology. Metabolism of 4‐HPR is of particular…”
Get full text

Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) by Fresneau, Brice, Hackshaw, A., Hawkins, D.S., Paulussen, M., Anderson, J.R., Judson, I., Litière, S., Dirksen, U., Lewis, I., den Berg, H., Gaspar, N., Gelderblom, H., Whelan, J., Boddy, A.V., Wheatley, K., Pignon, J.P., Vathaire, F., Deley, M.C., Teuff, G.

“…Background A marginal interaction between sex and the type of alkylating agent was observed for event‐free survival in the Euro‐EWING99‐R1 randomized…”
Get full text

Body surface area estimation in children using weight alone: application in paediatric oncology by SHARKEY, I, BODDY, A. V, WALLACE, H, MYCROFT, J, HOLLIS, R, PICTON, S

“…The majority of chemotherapy regimens and trials specify doses of cytotoxic drugs normalized to body surface area. Estimation of BSA in paediatric patients is…”
Get full text

Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - : a study of the United Kingdom Children's Cancer Study Group by VEAL, G. J, COLE, M, ERRINGTON, J, PEARSON, A. D. J, FOOT, A. B. M, WHYMAN, G, BODDY, A. V

“…The administration of 13-cis-retinoic acid (13-cisRA), following myeloablative therapy improves 3-year event-free survival rates in children with high-risk…”
Get full text

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells by ARMSTRONG, J. L, RUIZ, M, BODDY, A. V, REDFERN, C. P. F, PEARSON, A. D. J, VEAL, G. J

“…Recent data indicate that isomerisation to all-trans retinoic acid (ATRA) is the key mechanism underlying the favourable clinical properties of 13-cis retinoic…”
Get full text

Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma by Picton, S. V., Keeble, J., Holden, V., Errington, J., Boddy, A. V., Veal, G. J.

“…Introduction Carboplatin dosing based on renal function and therapeutic monitoring have been previously shown to be beneficial in the treatment of children…”
Get full text

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor by JAMIESON, D, TUNG, A. T. Y, KNOX, R. J, BODDY, A. V

“…NRH:Quinone Oxidoreductase 2 (NQO2) has been described as having no enzymatic activity with nicotinamide adenine dinucleotide (NADH) or NADPH as electron…”
Get full text

Genetics of Cisplatin Ototoxicity: Confirming the Unexplained? by Boddy, A V

“…Replication of findings in clinical pharmacogenetic studies is essential but often neglected. The observation that TPMT and COMT genotypes, in combination with…”
Get full text

Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours by VEAL, G. J, ERRINGTON, J, BODDY, A. V, TILBY, M. J, PEARSON, A. D. J, FOOT, A. B. M, MCDOWELL, H, ELLERSHAW, C, PIZER, B, NOWELL, G. M, PEARSON, D. G

“…A pharmacokinetic-pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose…”
Get full text

Estimation of renal function and its potential impact on carboplatin dosing in children with cancer by Chinnaswamy, G, Cole, M, Boddy, A V, Keir, M, Price, L, Parry, A, English, M, Veal, G J

“…Renal function-based carboplatin dosing is used routinely in paediatric oncology clinical practice. It is important that accurate assessments of renal function…”
Get full text

A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin by VEAL, G. J, GRIFFIN, M. J, PEARSON, A. D. J, WELBANK, H, BODDY, A. V, PRICE, E, PARRY, A, DICK, G. S, LITTLE, M. A, YULE, S. M, MORLAND, B, ESTLIN, E. J, HALE, J. P

“…Pre-clinical studies indicate that cisplatin encapsulated in STEALTH((R))liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity,…”
Get full text

Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re‐evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function by Duong, J.K., Veal, G.J., Nath, C.E., Shaw, P.J., Errington, J., Ladenstein, R., Boddy, A.V.

“…Aims Carboplatin dosage is calculated by using the estimated glomerular filtration rate (GFR) to achieve a target plasma area under the plasma…”
Get full text

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia by Vormoor, B., Veal, G. J., Griffin, M. J., Boddy, A. V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K. E., Tall, J. R., Moore, A. S., Toguchi, M., Acton, G., Dyer, K., Schwab, C., Harrison, C. J., Grainger, J. D., Lancaster, D., Kearns, P., Hargrave, D., Vormoor, J.

“…Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify…”
Get full text

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer by WILLITS, I, PRICE, L, PARRY, A, TILBY, Mj, FORD, D, CHOLERTON, S, PEARSON, Adj, BODDY, Av

“…The degree of damage to DNA following ifosfamide (IFO) treatment may be linked to the therapeutic efficacy. The pharmacokinetics and metabolism of IFO were…”
Get full text